Aardvark Therapeutics, Inc. (AARD)
5.27
+0.21
(+4.15%)
USD |
NASDAQ |
Sep 28, 16:00
5.27
0.00 (0.00%)
After-Hours: 20:00
Aardvark Therapeutics Enterprise Value : 37.54M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 37.54M |
| September 24, 2026 | 48.26M |
| September 23, 2026 | 48.48M |
| September 22, 2026 | 52.64M |
| September 21, 2026 | 48.70M |
| September 18, 2026 | 44.54M |
| September 17, 2026 | 47.83M |
| September 16, 2026 | 39.51M |
| September 15, 2026 | 36.67M |
| September 14, 2026 | 48.26M |
| September 11, 2026 | 39.07M |
| September 10, 2026 | 36.45M |
| September 09, 2026 | 34.48M |
| September 08, 2026 | 43.45M |
| September 04, 2026 | 44.54M |
| September 03, 2026 | 52.20M |
| September 02, 2026 | 57.02M |
| September 01, 2026 | 56.36M |
| August 31, 2026 | 60.30M |
| August 28, 2026 | 53.52M |
| August 27, 2026 | 71.68M |
| August 26, 2026 | 75.84M |
| August 25, 2026 | 85.47M |
| August 24, 2026 | 77.37M |
| August 21, 2026 | 76.06M |
| Date | Value |
|---|---|
| August 20, 2026 | 55.70M |
| August 19, 2026 | 74.53M |
| August 18, 2026 | 61.29M |
| August 17, 2026 | 74.31M |
| August 14, 2026 | 69.93M |
| August 13, 2026 | 67.08M |
| August 12, 2026 | 70.59M |
| August 11, 2026 | 84.15M |
| August 10, 2026 | 92.25M |
| August 07, 2026 | 99.69M |
| August 06, 2026 | 86.56M |
| August 05, 2026 | 91.38M |
| August 04, 2026 | 85.03M |
| August 03, 2026 | 81.75M |
| July 31, 2026 | 71.24M |
| July 30, 2026 | 66.87M |
| July 29, 2026 | 43.23M |
| July 28, 2026 | 67.30M |
| July 27, 2026 | 73.21M |
| July 24, 2026 | 65.12M |
| July 23, 2026 | 66.65M |
| July 22, 2026 | 68.62M |
| July 21, 2026 | 59.86M |
| July 20, 2026 | 47.83M |
| July 17, 2026 | 55.05M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.935B |
| Corcept Therapeutics, Inc. | 12.23B |
| Veru, Inc. | 20.20M |
| Johnson & Johnson | 681.44B |
| Eli Lilly & Co. | 1.160T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.39M |
| Total Expenses (Quarterly) | 14.39M |
| EPS Diluted (Quarterly) | -0.6586 |
| Earnings Yield | -60.82% |
| Normalized Earnings Yield | -60.82 |